Upcoming Events.


January 7th 2019 - January 10th 2019

37th Annual J.P. Morgan Health Care Investor Conference

Venue:    San Francisco, California, USA

March 3rd 2019 - March 5th 2019

Day 2 – Tuesday 5th March/ 3.00 p.m.  

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

Venue:  Grand Hyatt, San Diego, USA

Past Events.


November 27th 2018 - November 29th 2018

conference day 1/ 02.00 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab

Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany

November 16th 2018
November 8th 2018

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Macquarie Office -  Sydney, Australia

click here for agenda

November 7th 2018 - November 11th 2018

The company will have presentations at the conference and representatives will be attending.

Venue:    Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA

October 30th 2018

day 2/ 2:55 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor
(Eftilagimod Alpha) with Pembrolizumab

click here for agenda / day 2

click here for presentation

Venue:   Basel Congress Center, Basel, Switzerland

October 30th 2018

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Sofitel Melbourne on Collins, Melbourne VIC 3000, Australia

click here to view program of the event

October 24th 2018 - October 27th 2018

Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:

"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."

Venue: Manchester Central Convention Complex, Manchester, United Kingdom

October 19th 2018 - October 23rd 2018

Representatives of the company will be attending the conference.

Venue:   Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de

October 2nd 2018

Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

September 7th 2018

BioCentury 25th Annual NewsMakers - Biotech Industry Conference

Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day. 

Venue:  Millenium Broadway Hotel & Conference Center, NY, USA

Press release: click here

Download "Newsmaker Immutep Corporate Presentation"

Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018

 

June 20th 2018

 - the largest networking event for life sciences and healthcare industries in the German capital region -

Venue:    Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany

June 1st 2018

Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018

June 1st 2018

Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018

May 24th 2018 - May 25th 2018

Frédéric Triebel speaks on the subject:

“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”

May 16th 2018 - May 18th 2018
April 18th 2018 - April 19th 2018

Venue:  bbc (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany

April 14th 2018 - April 18th 2018
April 9th 2018 - April 10th 2018

Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9th

Venue:  Essex House, New York, NY, USA

Finance News Network Interview, 12. Nov. 2018, Immutep Limited (ASX:IMM) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key milestones.

Your Money - Interview with Marc Voigt (CEO), 31.10.2018

Finance News Network - Interview with Marc Voigt (CEO), 06.09.18

FNN – Interview with Immutep

Sky Business News - Interview with Marc Voigt (CEO), 30.04.18

Interview with Frédéric Triebel and Marc Voigt

CNBC - Interview with Marc Voigt (CEO)

Sky Business News - Interview with Marc Voigt (CEO), 25.11.15

The Business - Interview with Lucy Turnbull

Sky Business News - Interview with Marc Voigt (CEO), 16.05.14